糖酵解
化学
细胞外基质
癌症研究
细胞生物学
肿瘤微环境
间质细胞
胰腺癌
串扰
癌细胞
免疫疗法
癌相关成纤维细胞
细胞外
厌氧糖酵解
生物化学
组蛋白
免疫系统
内吞作用
癌症免疫疗法
缺氧(环境)
内化
作者
Yong Ma,Wenbo H. Liu,Mingdou Li,Tao Wang,Bin Zhao,Keshen Wang,Qichen He,Haonan Sun,Huiguo Qing,Xiaoying Guan,Wengui Shi,Long Qin,Yuman Dong,Huinian Zhou,Zeyuan Yu,Xiangyan Jiang,Zuoyi Jiao
标识
DOI:10.1002/advs.202514933
摘要
ABSTRACT Although glycolysis is a metabolic hallmark of pancreatic ductal adenocarcinoma (PDAC), it remains unclear whether the excessive lactate produced regulates CAF lactylation to promote extracellular matrix (ECM) deposition. The multi‐omics and spontaneous model findings indicate that lactate accumulation in the tumor microenvironment (TME) promotes histone H3 lysine 18 lactylation (H3K18la) and activation of cancer‐associated fibroblasts (CAFs), leading to both ECM densification and impaired immunotherapy efficacy in PDAC. Mechanistically, ubiquitin‐conjugating enzyme E2T (UBE2T) acts as an initiating factor that promotes p53 positive feedback degradation through modulation of ribosome biogenesis, thereby enhancing lactate metabolic crosstalk via glycolytic reprogramming. Genetic ablation or pharmacological inhibition of UBE2T using the selective inhibitor pentagalloylglucose (PGG) disrupts lactate metabolic crosstalk, suppresses stromal deposition, and promotes intratumoral CD8 + T cells infiltration. Furthermore, the combination of PGG and anti‐PD‐1 therapy exhibits synergistic effects and survival benefits in spontaneous PDAC mice and immune‐reconstituted patient‐derived xenografts. Collectively, these findings reveal that UBE2T drives p53 positive feedback degradation to enhance glycolysis of PDAC, leading to excessive lactate production, which promotes H3K18la in CAFs and subsequent ECM deposition. Targeting UBE2T represents a potential strategy to improve the efficacy of immunotherapy in PDAC.
科研通智能强力驱动
Strongly Powered by AbleSci AI